Fig. 1

Study CONSORT diagram. Across three centers, 155 breast cancer patients scheduled to begin neoadjuvant chemotherapy were assessed for eligibility. Forty-eight percent were eligible for the study, and 19 women were enrolled. Of the 10 women in the control group, one withdrew after her first chemotherapy infusion and three had significant side effects to chemotherapy which resulted in loss to follow up for exercise testing. In the intervention group, one patient withdrew one week following randomization and another patient was lost to follow up for inability to schedule testing